'3D' test could reduce reliance on animals
To determine whether new medicines are safe and effective for humans, researchers must first test them in animals, which is costly and time-consuming, as well as ethically challenging. In a study published in ACS' journal Molecular Pharmaceutics, scientists report that they've developed a simple, "3D" laboratory method to test asthma and allergy medications that mimics what happens in the body, which could help reduce the need for animal testing.
Amir Ghaemmaghami and colleagues note that respiratory conditions, such as asthma and allergies, are becoming more common. These conditions affect the lungs and the airway leading to the lungs, making it difficult to breathe. Every year, respiratory symptoms lead to expensive hospital visits, as well as absences from work and school. Better drugs could provide relief, but before giving new medicines to people, researchers must first test them in animals — a costly and laborious process. Sometimes, researchers will use "2D" tests in which they apply the drug to a layer of human cells in a lab dish instead, but this isn't an adequate way to tell how a medicine will work in a whole animal or a whole person. So, Ghaemmaghami's team developed a new, 3D alternative.
Their test includes three types of human cells that are typically in a person's airway. In the body, these cells are close together and are involved in the development of respiratory conditions. The 3D "model" reacted just like a real person's airway when they exposed it to allergens and bacterial extract. They say that the model has the potential of reducing the need for some animal testing of new drugs for respiratory conditions.
Most read news
Organizations
Other news from the department science

New Label-Free Imaging Tracks Cancer Treatment in Single Cells
One Tool, Many Applications

The evolution of cancer cells decoded
"Our vision is a new type of early cancer detection"

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Lipoid_congenital_adrenal_hyperplasia

Making spines from sea water
Nadolol
Pain_withdrawal_reflex
Dok-7

Gut microbiome as a predictive factor for kidney rejection? - Study establishes a link between microbial changes in the gut microbiome and transplant rejection and graft dysfunction
History_of_intersex_surgery
Latent_tuberculosis
Category:Enzymes_of_known_structure

Detect neurodegenerative diseases such as Alzheimer's by a simple eye scan? - Milestone on the way to early diagnostics: Researchers use spectroscopic means to decipher the biochemical composition of the retina
Alexia_(disorder)
